Please wait a minute...
Reviews in Cardiovascular Medicine  2020, Vol. 21 Issue (2): 163-179     DOI: 10.31083/j.rcm.2020.02.597
Review Previous articles | Next articles
Current and emerging therapeutic approaches to pulmonary hypertension
Malik Bisserier1, *(), Natasha Pradhan1, Lahouaria Hadri1
1Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Download:  PDF(4618KB)  ( 1561 ) Full text   ( 55 )
Export:  BibTeX | EndNote (RIS)      
Abstract:

Pulmonary arterial hypertension (PAH) is a progressive and fatal lung disease of multifactorial etiology. Most of the available drugs and FDA-approved therapies for treating pulmonary hypertension attempt to overcome the imbalance between vasoactive and vasodilator mediators, and restore the endothelial cell function. Traditional medications for treating PAH include the prostacyclin analogs and receptor agonists, phosphodiesterase 5 inhibitors, endothelin-receptor antagonists, and cGMP activators. While the current FDA-approved drugs showed improvements in quality of life and hemodynamic parameters, they have shown only very limited beneficial effects on survival and disease progression. None of them offers a cure against PAH, and the median survival rate remains less than three years from diagnosis. Extensive research efforts have led to the emergence of innovative therapeutic approaches in the area of PAH. In this review, we provide an overview of the current FDA-approved therapies in PAH and discuss the associated clinical trials and reported-side effects. As recent studies have led to the emergence of innovative therapeutic approaches in the area of PAH, we also focus on the latest promising therapies in preclinical studies such as stem cell-based therapies, gene transfer, and epigenetic therapies.

Key words:  Pulmonary hypertension      FDA      clinical trial      treatment      gene therapy      epigenetics     
Submitted:  19 November 2019      Revised:  22 May 2020      Accepted:  25 May 2020      Published:  30 June 2020     
Fund: NIH R01 HL133554;AHA Innovative Project Award 18IPA34170321;NIH 5T32HL007824-22;Cardiovascular Medical Research and Education Fund (CMREF)
*Corresponding Author(s):  Malik Bisserier     E-mail:  Malik.bisserier@mssm.edu

Cite this article: 

Malik Bisserier, Natasha Pradhan, Lahouaria Hadri. Current and emerging therapeutic approaches to pulmonary hypertension. Reviews in Cardiovascular Medicine, 2020, 21(2): 163-179.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm.2020.02.597     OR     https://rcm.imrpress.com/EN/Y2020/V21/I2/163

Figure 1.  Updated classification of pulmonary hypertension. This classification is based on recommendations from the 5th World Symposium on Pulmonary Hypertension in Nice, France, 2013. The World Health Organization classifies PAH into five broad groups of pulmonary hypertension based on the clinical similarities. The five groups of PH are: 1-PAH, 2-PH associated with left heart disease, 3- PH associated with chronic lung disease and/or hypoxia, 4- chronic thromboembolic PH (CTEPH) and 5- PH with unclear or multifactorial mechanisms.

Figure 2.  Pathogenesis of pulmonary hypertension. PAH is characterized by a vascular remodeling of distal pulmonary arteries, vasoconstriction, endothelial dysfunction, inflammation and thrombosis leading to the formation of plexiform lesions. Proliferation and migration of pulmonary endothelial cells (PAECs) and pulmonary artery smooth muscle cells (PASMCs) contribute to the vascular muscularization and obstruction, which progressively increase vascular resistance in PAH and induce right ventricle (RV) hypertrophy and ultimately RV dysfunction.

Figure 3.  Pathways targeted by the current FDA-approved PAH therapies. FDA-approved PAH therapies target mostly three major pathways: prostacyclin, endothelin (ET), nitric oxide (NO). They fall into four categories: 1- Prostacyclin Analogues and receptor agonists (epoprostenol, tetroprostinil, iloprost, selexipag), 2- Phosphodiesterase 5 inhibitors (sildenafil, tadalafil), 3- ET receptor antagonists (ambrisentan, bosentan, macitentan), 4- cGMP activators (riociguat).

Figure 4.  Stem cell-based therapy, gene transfer and epigenetic therapy as promising innovative strategies for treating pulmonary hypertension. Recent preclinical studies suggested that stem cell-based therapies, gene transfer and epigenetic-based therapies may offer a new perspective in the treatment of PAH. Administration of endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), intratracheal administration of inhaled-adenovirus encoding for BMPR2 or gene delivery of adeno-associated virus (AAV) serotype 1 encoding for human SERCA2a prevented and reversed the development of PH in preclinical animal models of PAH by blocking cardiac/arterial remodeling and improving hemodynamic abnormalities (RVSP, mPAP). Increasing evidence suggests that epigenetic-based therapies, such as DNMT, HDAC and BET inhibitors, may be of great therapeutic potential for treating PAH.

1 Aguero, J., Ishikawa, K., Hadri, L., Santos-Gallego, C. G., Fish, K. M., Kohlbrenner, E., Hammoudi, N., Kho, C., Lee, A., Ibanez, B., Garcia-Alvarez, A., Zsebo, K., Maron, B. A., Plataki, M., Fuster, V., Leopold, J. A. and Hajjar, R. J. (2016) Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model. Journal of the American College of Cardiology 67, 2032-2046.
doi: 10.1016/j.jacc.2016.02.049 pmid: 27126531
2 Alison, M. R., Poulsom, R., Forbes, S. and Wright, N. A. (2002) An introduction to stem cells. The Journal of Pathology 197, 419-423.
doi: 10.1002/path.1187 pmid: 12115858
3 Archer, S. L., Marsboom, G., Kim, G. H., Zhang, H. J., Toth, P. T., Svensson, E. C., Dyck, J. R., Gomberg-Maitland, M., Thebaud, B., Husain, A. N., Cipriani, N. and Rehman, J. (2010) Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121, 2661-2671.
doi: 10.1161/CIRCULATIONAHA.109.916098 pmid: 20529999
4 Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G. and Isner, J. M. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967.
doi: 10.1126/science.275.5302.964 pmid: 9020076
5 Atkinson, C., Stewart, S., Upton, P. D., Machado, R., Thomson, J. R., Trembath, R. C. and Morrell, N. W. (2002) Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672-1678.
doi: 10.1161/01.cir.0000012754.72951.3d pmid: 11940546
6 Auricchio, A., O'Connor, E., Weiner, D., Gao, G. P., Hildinger, M., Wang, L., Calcedo, R. and Wilson, J. M. (2002) Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation 110, 499-504.
doi: 10.1172/JCI15780 pmid: 12189244
7 Austin, E. D. and Loyd, J. E. (2014) The genetics of pulmonary arterial hypertension. Circulation Research 115, 189-202.
doi: 10.1161/CIRCRESAHA.115.303404
8 Badesch, D. B., McGoon, M. D., Barst, R. J., Tapson, V. F., Rubin, L. J., Wigley, F. M., Kral, K. M., Raphiou, I. H. and Crater, G. D. (2009) Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. Journal of Rheumatology 36, 2244-2249.
doi: 10.3899/jrheum.081277 pmid: 19723905
9 Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., Jobsis, M. M., Loyd, J. E., Murali, S., Frost, A., Girgis, R., Bourge, R. C., Ralph, D. D., Elliott, C. G., Hill, N. S., Langleben, D., Schilz, R. J., McLaughlin, V. V., Robbins, I. M., Groves, B. M., Shapiro, S. and Medsger, T. A., Jr. (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine 132, 425-434.
doi: 10.7326/0003-4819-132-6-200003210-00002 pmid: 10733441
10 Baliga, R. S., MacAllister, R. J. and Hobbs, A. J. (2011) New perspectives for the treatment of pulmonary hypertension. British Journal of Pharmacology 163, 125-140.
doi: 10.1111/j.1476-5381.2010.01164.x
11 Barst, R. (2010) How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? International Journal of Clinical Practice 23-32.
pmid: 9796552
12 Barst, R. J., McGoon, M., Torbicki, A., Sitbon, O., Krowka, M. J., Olschewski, H. and Gaine, S. (2004) Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of the American College of Cardiology 43, 40S-47S.
pmid: 15194177
13 Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., Koerner, S. K., Langleben, D., Keller, C. A., Murali, S., Uretsky, B. F., Clayton, L. M., Jobsis, M. M., Blackburn, S. D., Shortino, D., Crow, J. W. and Primary Pulmonary Hypertension Study, G. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine 334, 296-301.
doi: 10.1056/NEJM199602013340504 pmid: 8532025
14 Bisserier, M., Janostiak, R., Lezoualc’h, F. and Hadri, L. (2020) Targeting epigenetic mechanisms as an emerging therapeutic strategy in pulmonary hypertension disease. Vascular Biology 2, R17-R34.
doi: 10.1530/VB-19-0030
15 Brouwer, K. M., Hoogenkamp, H. R., Daamen, W. F. and van Kuppevelt, T. H. (2013) Regenerative medicine for the respiratory system: distant future or tomorrow's treatment? American Journal of Respiratory and Critical Care Medicine 187, 468-475.
pmid: 23220914
16 Buckley, M. S., Staib, R. L., Wicks, L. M. and Feldman, J. P. (2010) Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, 151-161.
doi: 10.2147/DHPS.S6215 pmid: 21701627
17 Burchfield, J. S. and Dimmeler, S. (2008) Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis & Tissue Repair 1, 4.
doi: 10.1186/1755-1536-1-4 pmid: 19014650
18 Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F. and Rubin, L. J. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123.
doi: 10.1016/S0140-6736(01)06250-X pmid: 11597664
19 Cheng, X., Wang, Y. and Du, L. (2019) Epigenetic modulation in the initiation and progression of pulmonary hypertension. Hypertension 74, 733-739.
pmid: 31476913
20 Chin, M., Levy, R. D., Yoshida, E. M. and Byrne, M. F. (2012) Sitaxsentan-induced acute severe hepatitis treated with glucocorticoid therapy. Canadian Respiratory Journal 19, e1-2.
pmid: 22332138
21 Cho, Y. K., Eom, G. H., Kee, H. J., Kim, H. S., Choi, W. Y., Nam, K. I., Ma, J. S. and Kook, H. (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circulation Journal 74, 760-770.
doi: 10.1253/circj.cj-09-0580 pmid: 20208383
22 Condon, D. F., Nickel, N. P., Anderson, R., Mirza, S. and de Jesus Perez, V. A. (2019) The 6th world symposium on pulmonary hypertension: what's old is new. F1000Research 8,
doi: 10.12688/f1000research.18846.1 pmid: 32477495
23 D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T. and et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Annals of Internal Medicine 115, 343-349.
doi: 10.7326/0003-4819-115-5-343 pmid: 1863023
24 Daya, S. and Berns, K. I. (2008) Gene therapy using adeno-associated virus vectors. Clinical Microbiology Reviews 21, 583-593.
doi: 10.1128/CMR.00008-08 pmid: 18854481
25 de Mendonca, L., Felix, N. S., Blanco, N. G., Da Silva, J. S., Ferreira, T. P., Abreu, S. C., Cruz, F. F., Rocha, N., Silva, P. M., Martins, V., Capelozzi, V. L., Zapata-Sudo, G., Rocco, P. R. M. and Silva, P. L. (2017) Mesenchymal stromal cell therapy reduces lung inflammation and vascular remodeling and improves hemodynamics in experimental pulmonary arterial hypertension. Stem Cell Research & Therapy 8, 220.
doi: 10.1186/s13287-017-0669-0 pmid: 28974252
26 Denton, C. P., Pope, J. E., Peter, H. H., Gabrielli, A., Boonstra, A., van den Hoogen, F. H., Riemekasten, G., De Vita, S., Morganti, A., Dolberg, M., Berkani, O., Guillevin, L., Scleroderma, T. R. U. i. P. a. w. and Connective Tissue Diseases, I. (2008) Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Annals of the Rheumatic Diseases 67, 1222-1228.
doi: 10.1136/ard.2007.079921 pmid: 18055477
27 Eckschlager, T., Plch, J., Stiborova, M. and Hrabeta, J. (2017) Histone Deacetylase Inhibitors as Anticancer Drugs. International Journal of Molecular Sciences 18, 1414
doi: 10.3390/ijms18071414
28 Fessel, J. P., Loyd, J. E. and Austin, E. D. (2011) The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulmonary Circulation 1, 305-319.
doi: 10.4103/2045-8932.87293 pmid: 22140620
29 Forstermann, U. and Sessa, W. C. (2012) Nitric oxide synthases: regulation and function. European Heart Journal 33, 829-837, 837a-837d.
30 Foster, W. S., Suen, C. M. and Stewart, D. J. (2014) Regenerative cell and tissue-based therapies for pulmonary arterial hypertension. Canadian Journal of Cardiology 30, 1350-1360.
doi: 10.1016/j.cjca.2014.08.022 pmid: 25442435
31 Galie, N., Barbera, J. A., Frost, A. E., Ghofrani, H. A., Hoeper, M. M., McLaughlin, V. V., Peacock, A. J., Simonneau, G., Vachiery, J. L., Grunig, E., Oudiz, R. J., Vonk-Noordegraaf, A., White, R. J., Blair, C., Gillies, H., Miller, K. L., Harris, J. H., Langley, J., Rubin, L. J. and Investigators, A. (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine 373, 834-844.
doi: 10.1056/NEJMoa1413687 pmid: 26308684
32 Galie, N., Brundage, B. H., Ghofrani, H. A., Oudiz, R. J., Simonneau, G., Safdar, Z., Shapiro, S., White, R. J., Chan, M., Beardsworth, A., Frumkin, L., Barst, R. J., Pulmonary Arterial, H. and Response to Tadalafil Study, G. (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119, 2894-2903.
doi: 10.1161/CIRCULATIONAHA.108.839274 pmid: 19470885
33 Galie, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., Grimminger, F., Kurzyna, M., Simonneau, G. and Sildenafil Use in Pulmonary Arterial Hypertension Study, G. (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353, 2148-2157.
doi: 10.1056/NEJMoa050010 pmid: 16291984
34 Galie, N., Humbert, M., Vachiery, J. L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., Ghofrani, A., Gomez Sanchez, M. A., Hansmann, G., Klepetko, W., Lancellotti, P., Matucci, M., McDonagh, T., Pierard, L. A., Trindade, P. T., Zompatori, M., Hoeper, M. and Group, E. S. C. S. D. (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). European Heart Journal 37, 67-119.
doi: 10.1093/eurheartj/ehv317 pmid: 26320113
35 Galie, N., McLaughlin, V. V., Rubin, L. J. and Simonneau, G. (2019) An overview of the 6th World symposium on pulmonary hypertension. European Respiratory Journal 53, 1802148.
doi: 10.1183/13993003.02148-2018 pmid: 30552088
36 Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Gerber, M. J., Dufton, C., Wiens, B. L., Rubin, L. J. and Ambrisentan in Pulmonary Arterial Hypertension, R. D.-B. P.-C. M. E. S. G. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019.
pmid: 18506008
37 Ghofrani, H. A., Barst, R. J., Benza, R. L., Champion, H. C., Fagan, K. A., Grimminger, F., Humbert, M., Simonneau, G., Stewart, D. J., Ventura, C. and Rubin, L. J. (2009) Future perspectives for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 54, S108-117.
doi: 10.1016/j.jacc.2009.04.014 pmid: 19555854
38 Ghofrani, H. A., Galie, N., Grimminger, F., Grunig, E., Humbert, M., Jing, Z. C., Keogh, A. M., Langleben, D., Kilama, M. O., Fritsch, A., Neuser, D., Rubin, L. J. and Group, P.-S. (2013) Riociguat for the treatment of pulmonary arterial hypertension. New England Journal of Medicine 369, 330-340.
doi: 10.1056/NEJMoa1209655 pmid: 23883378
39 Ghofrani, H. A., Hoeper, M. M., Halank, M., Meyer, F. J., Staehler, G., Behr, J., Ewert, R., Weimann, G. and Grimminger, F. (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. European Respiratory Journal 36, 792-799.
pmid: 20530034
40 Gomberg-Maitland, M. and Olschewski, H. (2008) Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal 31, 891-901.
doi: 10.1183/09031936.00097107 pmid: 18378784
41 Granton, J., Langleben, D., Kutryk, M. B., Camack, N., Galipeau, J., Courtman, D. W. and Stewart, D. J. (2015) Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circulation Research 117, 645-654.
doi: 10.1161/CIRCRESAHA.114.305951 pmid: 26195220
42 Gu, M., Shao, N. Y., Sa, S., Li, D., Termglinchan, V., Ameen, M., Karakikes, I., Sosa, G., Grubert, F., Lee, J., Cao, A., Taylor, S., Ma, Y., Zhao, Z., Chappell, J., Hamid, R., Austin, E. D., Gold, J. D., Wu, J. C., Snyder, M. P. and Rabinovitch, M. (2017) Patient-specific iPSC-derived endothelial cells uncover pathways that protect against pulmonary hypertension in BMPR2 mutation carriers. Cell Stem Cell 20, 490-504 e495.
doi: 10.1016/j.stem.2016.08.019 pmid: 28017794
43 Hadri, L., Kratlian, R. G., Benard, L., Maron, B. A., Dorfmuller, P., Ladage, D., Guignabert, C., Ishikawa, K., Aguero, J., Ibanez, B., Turnbull, I. C., Kohlbrenner, E., Liang, L., Zsebo, K., Humbert, M., Hulot, J. S., Kawase, Y., Hajjar, R. J. and Leopold, J. A. (2013) Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension. Circulation 128, 512-523.
pmid: 23804254
44 Harper, R. L., Maiolo, S., Ward, R. J., Seyfang, J., Cockshell, M. P., Bonder, C. S. and Reynolds, P. N. (2019) BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo. Respirology 24, 1095-1103.
doi: 10.1111/resp.13552 pmid: 30977250
45 Huang, W. C., Ke, M. W., Cheng, C. C., Chiou, S. H., Wann, S. R., Shu, C. W., Chiou, K. R., Tseng, C. J., Pan, H. W., Mar, G. Y. and Liu, C. P. (2016) Therapeutic benefits of induced pluripotent stem cells in monocrotaline-induced pulmonary arterial hypertension. PLoS One 11, e0142476.
doi: 10.1371/journal.pone.0142476 pmid: 26840075
46 Hynynen, M. M. and Khalil, R. A. (2006) The vascular endothelin system in hypertension--recent patents and discoveries. Recent Patents on Cardiovascular Drug Discovery 1, 95-108.
doi: 10.2174/157489006775244263 pmid: 17200683
47 Jing, Z. C., Yu, Z. X., Shen, J. Y., Wu, B. X., Xu, K. F., Zhu, X. Y., Pan, L., Zhang, Z. L., Liu, X. Q., Zhang, Y. S., Jiang, X., Galie, N., Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension Study, G. (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. American Journal of Respiratory and Critical Care Medicine 183, 1723-1729.
pmid: 21471085
48 Kanki-Horimoto, S., Horimoto, H., Mieno, S., Kishida, K., Watanabe, F., Furuya, E. and Katsumata, T. (2006) Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 114, I181-185.
doi: 10.1161/CIRCULATIONAHA.105.001487 pmid: 16820570
49 Kass, D. A. and Solaro, R. J. (2006) Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 113, 305-315.
doi: 10.1161/CIRCULATIONAHA.105.542407 pmid: 16418450
50 Katz, M. G., Fargnoli, A. S., Gubara, S. M., Fish, K., Weber, T., Bridges, C. R., Hajjar, R. J. and Ishikawa, K. (2019) Targeted Gene Delivery through the Respiratory System: Rationale for Intratracheal Gene Transfer. Journal of Cardiovascular Development and Disease 6, 8.
doi: 10.3390/jcdd6010008
51 Kim, J., Hwangbo, C., Hu, X., Kang, Y., Papangeli, I., Mehrotra, D., Park, H., Ju, H., McLean, D. L., Comhair, S. A., Erzurum, S. C. and Chun, H. J. (2015) Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension. Circulation 131, 190-199.
doi: 10.1161/CIRCULATIONAHA.114.013339 pmid: 25336633
52 Lai, Y. C., Potoka, K. C., Champion, H. C., Mora, A. L. and Gladwin, M. T. (2014) Pulmonary arterial hypertension: the clinical syndrome. Circulation Research 115, 115-130.
doi: 10.1161/CIRCRESAHA.115.301146
53 Lalu, M. M., McIntyre, L., Pugliese, C., Fergusson, D., Winston, B. W., Marshall, J. C., Granton, J., Stewart, D. J. and Canadian Critical Care Trials, G. (2012) Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 7, e47559.
pmid: 23133515
54 Lambert, O. and Bandilla, D. (2012) Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Design, Development and Therapy 6, 235-244.
doi: 10.2147/DDDT.S31628 pmid: 23049244
55 Lee, C., Mitsialis, S. A., Aslam, M., Vitali, S. H., Vergadi, E., Konstantinou, G., Sdrimas, K., Fernandez-Gonzalez, A. and Kourembanas, S. (2012) Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 126, 2601-2611.
doi: 10.1161/CIRCULATIONAHA.112.114173 pmid: 23114789
56 Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zheng, Z., Shu, Y., Wu, X., Lei, J., Li, Y., Zhang, W., Yang, C., Wu, K., Wu, Y., Ho, S., Athiviraham, A., Lee, M. J., Wolf, J. M., Reid, R. R. and He, T. C. (2017) Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes & Diseases 4, 43-63.
doi: 10.1016/j.gendis.2017.04.001 pmid: 28944281
57 Lee, T. I. and Young, R. A. (2013) Transcriptional regulation and its misregulation in disease. Cell 152, 1237-1251.
doi: 10.1016/j.cell.2013.02.014 pmid: 23498934
58 Liang, O. D., Mitsialis, S. A., Chang, M. S., Vergadi, E., Lee, C., Aslam, M., Fernandez-Gonzalez, A., Liu, X., Baveja, R. and Kourembanas, S. (2011) Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 29, 99-107.
pmid: 20957739
59 Liu, D., Yan, Y., Chen, J. W., Yuan, P., Wang, X. J., Jiang, R., Wang, L., Zhao, Q. H., Wu, W. H., Simonneau, G., Qu, J. M. and Jing, Z. C. (2017) Hypermethylation of BMPR2 promoter occurs in patients with heritable pulmonary arterial hypertension and inhibits BMPR2 expression. American Journal of Respiratory and Critical Care Medicine 196, 925-928.
doi: 10.1164/rccm.201611-2273LE pmid: 28170297
60 Liu, Z., Wang, P., Chen, H., Wold, E. A., Tian, B., Brasier, A. R. and Zhou, J. (2017) Drug discovery targeting bromodomain-containing protein 4. Journal of Medicinal Chemistry 60, 4533-4558.
doi: 10.1021/acs.jmedchem.6b01761 pmid: 28195723
61 Loisel, F., Provost, B., Haddad, F., Guihaire, J., Amsallem, M., Vrtovec, B., Fadel, E., Uzan, G. and Mercier, O. (2018) Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy? Pulmonary Circulation 8, 2045893218755979.
doi: 10.1177/2045893218755979 pmid: 29480154
62 Long, L., Ormiston, M. L., Yang, X., Southwood, M., Graf, S., Machado, R. D., Mueller, M., Kinzel, B., Yung, L. M., Wilkinson, J. M., Moore, S. D., Drake, K. M., Aldred, M. A., Yu, P. B., Upton, P. D. and Morrell, N. W. (2015) Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine 21, 777-785.
doi: 10.1038/nm.3877 pmid: 26076038
63 Mahla, R. S.(2016) Stem Cells applications in regenerative medicine and disease therapeutics. International Journal of Cell Biology 2016,6940283.
64 Majed, B. H. and Khalil, R. A. (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacological Reviews 64, 540-582.
doi: 10.1124/pr.111.004770
65 McGoon, M. D. and Miller, D. P. (2012) REVEAL: a contemporary US pulmonary arterial hypertension registry. European Respiratory Review 21, 8-18.
doi: 10.1183/09059180.00008211 pmid: 22379169
66 McLaughlin, V. V., Benza, R. L., Rubin, L. J., Channick, R. N., Voswinckel, R., Tapson, V. F., Robbins, I. M., Olschewski, H., Rubenfire, M. and Seeger, W. (2010) Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology 55, 1915-1922.
doi: 10.1016/j.jacc.2010.01.027
67 McLaughlin, V. V., Oudiz, R. J., Frost, A., Tapson, V. F., Murali, S., Channick, R. N., Badesch, D. B., Barst, R. J., Hsu, H. H. and Rubin, L. J. (2006) Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 174, 1257-1263.
pmid: 16946127
68 Meloche, J., Potus, F., Vaillancourt, M., Bourgeois, A., Johnson, I., Deschamps, L., Chabot, S., Ruffenach, G., Henry, S., Breuils-Bonnet, S., Tremblay, E., Nadeau, V., Lambert, C., Paradis, R., Provencher, S. and Bonnet, S. (2015) Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circulation Research 117, 525-535.
doi: 10.1161/CIRCRESAHA.115.307004 pmid: 26224795
69 Mingozzi, F. and High, K. A. (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122, 23-36.
doi: 10.1182/blood-2013-01-306647 pmid: 23596044
70 Montani, D., Chaumais, M. C., Savale, L., Natali, D., Price, L. C., Jais, X., Humbert, M., Simonneau, G. and Sitbon, O. (2009) Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy 26, 813-825.
doi: 10.1007/s12325-009-0064-z
71 Montani, D., Gunther, S., Dorfmuller, P., Perros, F., Girerd, B., Garcia, G., Jais, X., Savale, L., Artaud-Macari, E., Price, L. C., Humbert, M., Simonneau, G. and Sitbon, O. (2013) Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases 8, 97.
doi: 10.1186/1750-1172-8-97 pmid: 23829793
72 Muller, S., Filippakopoulos, P. and Knapp, S. (2011) Bromodomains as therapeutic targets. Expert Expert Reviews in Molecular Medicine 13, e29.
doi: 10.1017/S1462399411001992 pmid: 21933453
73 Naso, M. F., Tomkowicz, B., Perry, W. L., 3rd and Strohl, W. R. (2017) Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs 31, 317-334.
doi: 10.1007/s40259-017-0234-5 pmid: 28669112
74 Nieminen, M. S., Fruhwald, S., Heunks, L. M., Suominen, P. K., Gordon, A. C., Kivikko, M. and Pollesello, P. (2013) Levosimendan: current data, clinical use and future development. Heart Lung Vessel 5, 227-245.
pmid: 24364017
75 Olschewski, H., Simonneau, G., Galie, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., Winkler, J., Sitbon, O., Popov, W., Ghofrani, H. A., Manes, A., Kiely, D. G., Ewert, R., Meyer, A., Corris, P. A., Delcroix, M., Gomez-Sanchez, M., Siedentop, H., Seeger, W. and Aerosolized Iloprost Randomized Study, G. (2002) Inhaled iloprost for severe pulmonary hypertension. New England Journal of Medicine 347, 322-329.
doi: 10.1056/NEJMoa020204 pmid: 12151469
76 Oudiz, R. J., Brundage, B. H., Galie, N., Ghofrani, H. A., Simonneau, G., Botros, F. T., Chan, M., Beardsworth, A., Barst, R. J. and Group, P. S. (2012) Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. Journal of the American College of Cardiology 60, 768-774.
doi: 10.1016/j.jacc.2012.05.004
77 Oudiz, R. J., Galie, N., Olschewski, H., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B., Harrison, B. C., Despain, D., Dufton, C., Rubin, L. J. and Group, A. S. (2009) Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 54, 1971-1981.
pmid: 19909879
78 Pfeifer, A. and Verma, I. M. (2001) Gene therapy: promises and problems. Annual Review of Genomics and Human Genetics 2, 177-211.
pmid: 11701648
79 Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galie, N., Ghofrani, H. A., Jansa, P., Jing, Z. C., Le Brun, F. O., Mehta, S., Mittelholzer, C. M., Perchenet, L., Sastry, B. K., Sitbon, O., Souza, R., Torbicki, A., Zeng, X., Rubin, L. J., Simonneau, G. and Investigators, S. (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New England Journal of Medicine 369, 809-818.
doi: 10.1056/NEJMoa1213917 pmid: 23984728
80 Pullamsetti, S. S. and de Jesus Perez, V. A. (2019) EpiHope for the treatment of pulmonary arterial hypertension: selective versus nonselective BET inhibition. American Journal of Respiratory and Critical Care Medicine 200, 1188-1190.
doi: 10.1164/rccm.201906-1235LE pmid: 31419389
81 Ranganath, S. H., Levy, O., Inamdar, M. S. and Karp, J. M. (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244-258.
pmid: 22385653
82 Reynolds, A. M., Xia, W., Holmes, M. D., Hodge, S. J., Danilov, S., Curiel, D. T., Morrell, N. W. and Reynolds, P. N. (2007) Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology 292, L1182-1192.
pmid: 17277049
83 Reynolds, P. N. (2011) Gene therapy for pulmonary hypertension: prospects and challenges. Expert Opinion on Biological Therapy 11, 133-143.
doi: 10.1517/14712598.2011.542139 pmid: 21219232
84 Rubin, L. J., Badesch, D. B., Barst, R. J., Galie, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., Landzberg, M. and Simonneau, G. (2002) Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine 346, 896-903.
doi: 10.1056/NEJMoa012212 pmid: 11907289
85 Rubin, L. J., Badesch, D. B., Fleming, T. R., Galie, N., Simonneau, G., Ghofrani, H. A., Oakes, M., Layton, G., Serdarevic-Pehar, M., McLaughlin, V. V., Barst, R. J. and Group, S.-S. (2011) Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 140, 1274-1283.
pmid: 21546436
86 Rubin, L. J., Mendoza, J., Hood, M., McGoon, M., Barst, R., Williams, W. B., Diehl, J. H., Crow, J. and Long, W. (1990) Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Annals of Internal Medicine 112, 485-491.
pmid: 2107780
87 Sakao, S Tatsumi, K. and Voelkel, N. F. (2009) Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respiratory Research 10, 95.
doi: 10.1186/1465-9921-10-95 pmid: 19825167
88 Seto, E. and Yoshida, M. (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harbor Perspectives in Biology 6, a018713.
doi: 10.1101/cshperspect.a018713 pmid: 24691964
89 Shimoda, L. A. and Laurie, S. S. (2013) Vascular remodeling in pulmonary hypertension. Journal of Molecular Medicine 91, 297-309.
doi: 10.1007/s00109-013-0998-0 pmid: 23334338
90 Simonneau, G., Barst, R. J., Galie, N., Naeije, R., Rich, S., Bourge, R. C., Keogh, A., Oudiz, R., Frost, A., Blackburn, S. D., Crow, J. W., Rubin, L. J. and Treprostinil Study, G. (2002) Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 165, 800-804.
doi: 10.1164/ajrccm.165.6.2106079 pmid: 11897647
91 Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., Olschewski, H., Robbins, I. M. and Souza, R. (2013) Updated clinical classification of pulmonary hypertension. Journal of the American College of Cardiology 62, D34-41.
doi: 10.1016/j.jacc.2013.10.029 pmid: 24355639
92 Simonneau, G., Rubin, L. J., Galie, N., Barst, R. J., Fleming, T. R., Frost, A. E., Engel, P. J., Kramer, M. R., Burgess, G., Collings, L., Cossons, N., Sitbon, O., Badesch, D. B. and Group, P. S. (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Annals of Internal Medicine 149, 521-530.
doi: 10.7326/0003-4819-149-8-200810210-00004 pmid: 18936500
93 Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galie, N., Ghofrani, H. A., Hoeper, M. M., Lang, I. M., Preiss, R., Rubin, L. J., Di Scala, L., Tapson, V., Adzerikho, I., Liu, J., Moiseeva, O., Zeng, X., Simonneau, G., McLaughlin, V. V. and Investigators, G. (2015) Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine 373, 2522-2533.
pmid: 26699168
94 Sitbon, O. and Morrell, N. (2012) Pathways in pulmonary arterial hypertension: the future is here. European Respiratory Rev 21, 321-327.
doi: 10.1183/09059180.00004812
95 Sitbon, O. and Vonk Noordegraaf, A. (2017) Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. European Respiratory Review 26,
doi: 10.1183/16000617.0061-2017 pmid: 29070579
96 Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Bill, M., Aldred, M. A., van de Veerdonk, M. C., Vonk Noordegraaf, A., Long-Boyle, J., Dash, R., Yang, P. C., Lawrie, A., Swift, A. J., Rabinovitch, M. and Zamanian, R. T. (2015) Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 192, 254-257.
doi: 10.1164/rccm.201411-2061LE pmid: 26177174
97 Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., Li, C. G., El-Bizri, N., Sawada, H., Haghighat, R., Chan, R., Haghighat, L., de Jesus Perez, V., Wang, L., Reddy, S., Zhao, M., Bernstein, D., Solow-Cordero, D. E., Beachy, P. A., Wandless, T. J., Ten Dijke, P. and Rabinovitch, M. (2013) FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation 123, 3600-3613.
pmid: 23867624
98 Stamm, J. A., Risbano, M. G. and Mathier, M. A. (2011) Overview of current therapeutic approaches for pulmonary hypertension. Pulmonary Circulation 1, 138-159.
doi: 10.4103/2045-8932.83444 pmid: 22034603
99 Strauss, B., Sassi, Y., Bueno-Beti, C., Ilkan, Z., Raad, N., Cacheux, M., Bisserier, M., Turnbull, I. C., Kohlbrenner, E., Hajjar, R. J., Hadri, L. and Akar, F. G. (2019) Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 127, 20-30.
pmid: 30502350
100 Suen, C. M., Mei, S. H., Kugathasan, L. and Stewart, D. J. (2013) Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases. Comprehensive Physiology 3, 1749-1779.
doi: 10.1002/cphy.c120034 pmid: 24265244
101 Tapson, V. F., Gomberg-Maitland, M., McLaughlin, V. V., Benza, R. L., Widlitz, A. C., Krichman, A. and Barst, R. J. (2006) Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129, 683-688.
doi: 10.1378/chest.129.3.683 pmid: 16537868
102 Umar, S., de Visser, Y. P., Steendijk, P., Schutte, C. I., Laghmani el, H., Wagenaar, G. T., Bax, W. H., Mantikou, E., Pijnappels, D. A., Atsma, D. E., Schalij, M. J., van der Wall, E. E. and van der Laarse, A. (2009) Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. American Journal of Physiology: Heart and Circulatory Physiology 297, H1606-1616.
doi: 10.1152/ajpheart.00590.2009 pmid: 19783775
103 Van der Feen, D. E., Kurakula, K., Tremblay, E., Boucherat, O., Bossers, G. P. L., Szulcek, R., Bourgeois, A., Lampron, M. C., Habbout, K., Martineau, S., Paulin, R., Kulikowski, E., Jahagirdar, R., Schalij, I., Bogaard, H. J., Bartelds, B., Provencher, S., Berger, R. M. F., Bonnet, S. and Goumans, M. J. (2019) Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine 200, 910-920.
pmid: 31042405
104 Ventetuolo, C. E. and Klinger, J. R. (2012) WHO Group 1 pulmonary arterial hypertension: current and investigative therapies. Progress in Cardiovascular Diseases 55, 89-103.
pmid: 23009906
105 Via, A. G., Frizziero, A. and Oliva, F. (2012) Biological properties of mesenchymal Stem Cells from different sources. Muscle, Ligaments and Tendons Journal 2, 154-162.
106 Wang, X. X., Zhang, F. R., Shang, Y. P., Zhu, J. H., Xie, X. D., Tao, Q. M., Zhu, J. H. and Chen, J. Z. (2007) Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. Journal of the American College of Cardiology 49, 1566-1571.
doi: 10.1016/j.jacc.2006.12.037 pmid: 17418297
107 Watanabe, S., Ishikawa, K., Plataki, M., Bikou, O., Kohlbrenner, E., Aguero, J., Hadri, L., Zarragoikoetxea, I., Fish, K., Leopold, J. A. and Hajjar, R. J. (2018) Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension. Pulmonary Circulation 8, 2045894018799738.
pmid: 30129881
108 Wei, A., Gu, Z., Li, J., Liu, X., Wu, X., Han, Y. and Pu, J. (2016) Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind placebo-Controlled Clinical Trials. Journal of the American Heart Association 5,
pmid: 27998918
109 Weinhold, B. (2006) Epigenetics: the science of change. Environ Health Perspect 114, A160-167.
doi: 10.1289/ehp.114-a160 pmid: 16507447
110 Weiss, D. J., Bertoncello, I., Borok, Z., Kim, C., Panoskaltsis-Mortari, A., Reynolds, S., Rojas, M., Stripp, B., Warburton, D. and Prockop, D. J. (2011) Stem cells and cell therapies in lung biology and lung diseases. Proceedings of the American Thoracic Society 8, 223-272.
pmid: 21653527
111 Wharton, J., Strange, J. W., Moller, G. M., Growcott, E. J., Ren, X., Franklyn, A. P., Phillips, S. C. and Wilkins, M. R. (2005) Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. American Journal of Respiratory and Critical Care Medicine 172, 105-113.
doi: 10.1164/rccm.200411-1587OC pmid: 15817798
112 Wilkins, M. R., Wharton, J., Grimminger, F. and Ghofrani, H. A. (2008) Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. European Respiratory Journal 32, 198-209.
doi: 10.1183/09031936.00124007 pmid: 18591337
113 Yoder, M. C. (2012) Human endothelial progenitor cells. Cold Spring Harbor Perspectives in Medicine 2, a006692.
doi: 10.1101/cshperspect.a006692 pmid: 22762017
114 Zhao, L., Chen, C. N., Hajji, N., Oliver, E., Cotroneo, E., Wharton, J., Wang, D., Li, M., McKinsey, T. A., Stenmark, K. R. and Wilkins, M. R. (2012) Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126, 455-467.
pmid: 22711276
115 Zhao, Y. D., Courtman, D. W., Deng, Y., Kugathasan, L., Zhang, Q. and Stewart, D. J. (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circulation Research 96, 442-450.
pmid: 15692087
116 Zhu, J. H., Wang, X. X., Zhang, F. R., Shang, Y. P., Tao, Q. M., Zhu, J. H. and Chen, J. Z. (2008) Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 12, 650-655.
doi: 10.1111/j.1399-3046.2007.00863.x pmid: 18466198
[1] Faeq Husain-Syed, Horst-Walter Birk, Khodr Tello, Manuel J. Richter, Claudio Ronco, Peter A. McCullough, Tanja Schörmann, Fiorenza Ferrari, Gökhan Yücel, Babak Yazdani, Hans-Dieter Walmrath, Werner Seeger, Henning Gall, H. Ardeschir Ghofrani. Alterations in Doppler-derived renal venous stasis index during decompensation of right heart failure and fluid overload in a patient with pulmonary hypertension[J]. Reviews in Cardiovascular Medicine, 2019, 20(4): 263-266.
[2] Jing Jin, Yufeng Liu, Lihong Huang, Hong Tan. Advances in epigenetic regulation of vascular aging[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 19-25.
[3] Yun Tian, Pingji Deng, Bing Li, Jieqiong Wang, Ju Li, Yulan Huang, Yan Zheng. Treatment models of cardiac rehabilitation in patients with coronary heart disease and related factors affecting patient compliance[J]. Reviews in Cardiovascular Medicine, 2019, 20(1): 27-33.
[4] Davide Bolignano, Anna Pisano, Graziella D’Arrigo. Pulmonary hypertension: a neglected risk condition in renal patients?[J]. Reviews in Cardiovascular Medicine, 2018, 19(4): 117-121.
[5] Georgios K. Efthimiadis, Efstathios Pagourelias, Thomas Zegkos, Despoina Parcharidou, Theofilos Panagiotidis, Alexandra Arvanitaki, Pavlos Rouskas, Haralambos Karvounis. An Overview of Pharmacotherapy in Hypertrophic Cardiomyopathy: Current Speculations and Clinical Perspectives[J]. Reviews in Cardiovascular Medicine, 2016, 17(3-4): 115-123.
[6] Tariq Bhat, Adi Neuman, Mohmad Tantary, Hilal Bhat, Daniel Glass, William Mannino, Muhammad Akhtar, Alina Bhat, Sumaya Teli, James Lafferty. Inhaled Nitric Oxide in Acute Pulmonary Embolism: A Systematic Review[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 1-8.
[7] Elena Giulia Milano, Mariantonietta Cicoira. Emerging Strategies for Chronic Heart Failure: The Role of Gene Therapy[J]. Reviews in Cardiovascular Medicine, 2012, 13(4): 161-168.
[8] Michael S. Lee, Ehtisham Mahmud. Percutaneous Revascularization for Left Main Coronary Artery Compression From Pulmonary Artery Enlargement Due to Pulmonary Hypertension[J]. Reviews in Cardiovascular Medicine, 2012, 13(1): 32-36.
[9] Timothy A. Sanborn. Bifurcation Classification Schemes: Impact of Lesion Morphology on Development of a Treatment Strategy[J]. Reviews in Cardiovascular Medicine, 2010, 11(S1): 11-16.
[10] Vishal Kapur, Christopher V. Chien, Justin E. Fuess, Ernst R. Schwarz. The Relationship Between Erectile Dysfunction and Cardiovascular Disease. Part II: The Role of PDE-5 Inhibition in Sexual Dysfunction and Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2008, 9(3): 187-195.
[11] Gregg C. Fonarow. Acute Decompensated Heart Failure: Challenges and Opportunities[J]. Reviews in Cardiovascular Medicine, 2007, 8(S5): 3-12.
[12] Marc A. Pfeffe, Scott D. Solomon, Peter Ivanovich, Ajay K. Singh, John J. V. McMurra. Uncertainty in the treatment of anemia in chronic kidney disease[J]. Reviews in Cardiovascular Medicine, 2005, 6(S3): 35-41.
[13] Mitchell T. Saltzberg. Beneficial Effects of Early Initiation of Vasoactive Agents in Patients With Acute Decompensated Heart Failure[J]. Reviews in Cardiovascular Medicine, 2004, 5(S4): 17-27.
[14] Jessica D. Grossman, William Grossman. Angiogenesis[J]. Reviews in Cardiovascular Medicine, 2002, 3(3): 138-144.
[15] . Best of the AHA Scientific Sessions 2001[J]. Reviews in Cardiovascular Medicine, 2002, 3(1): 22-48.
No Suggested Reading articles found!